Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Sign Up to like & getrecommendations! Published in 2017 at "Ophthalmology"
DOI: 10.1016/j.ophtha.2017.03.057
Abstract: PURPOSE To compare the efficacy and safety of brolucizumab with aflibercept to treat neovascular age-related macular degeneration (AMD). DESIGN Prospective, randomized, double-masked, multicenter, 2-arm, phase 2 study. PARTICIPANTS Eighty-nine treatment-naïve participants, aged ≥50 years, with… read more here.
Keywords: week; brolucizumab; treatment; versus aflibercept ... See more keywords
Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials
Sign Up to like & getrecommendations! Published in 2022 at "Ophthalmologica"
DOI: 10.1159/000524096
Abstract: Introduction: Neovascular age-related macular degeneration (nAMD) is characterized by exudation of fluid from abnormally growing blood vessels in the macula. Anti-vascular endothelial growth factor (VEGF) therapy is standard treatment for nAMD. Fluid resolution is used… read more here.
Keywords: hawk harrier; versus aflibercept; brolucizumab versus; hawk ... See more keywords